Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Christopher W RyanMark J Ratain

Abstract

Atrasentan is an orally bioavailable selective antagonist of the endothelin receptor ET(A). Due to the potential activity of this agent against prostate cancer, the majority of subjects enrolled in prior studies had been male. This Phase I study sought to determine the toxicity and pharmacokinetics of daily atrasentan in a population of both female and male subjects with advanced malignancies. Patients with refractory malignancies received atrasentan once daily at doses ranging from 5 mg to 75 mg. At least 3 subjects were treated at each dose level before enrollment began at the next higher dose level. Enrollment for specific dose levels was expanded if any subject experienced serious drug-related toxicity. Plasma concentration profiles for atrasentan were determined after dosing on days 1 and 28. Thirty-five patients received atrasentan at doses from 5 mg to 75 mg. The most frequent drug-related adverse events were headache (60%), rhinitis (49%), and peripheral edema (31%). These toxicities were mild to moderate in severity and reversible on cessation of treatment. Dose escalation was stopped at the 75-mg dose level due to the occurrence of three severe adverse events (2 hyponatremia and 1 hypotension). Atrasentan was rapidly ...Continue Reading

References

May 1, 1991·The Journal of Clinical Investigation·M ShichiriF Marumo
Aug 10, 1995·The New England Journal of Medicine·E R Levin
Mar 15, 1993·Annals of Internal Medicine·K H PoldermanL J Gooren
Mar 1, 1993·Peptides·B BattistiniP Sirois
Jun 1, 1996·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·A E BonomiR Zittoun
Jan 1, 1996·Pharmacology & Therapeutics·G A Gray, D J Webb
Feb 5, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S MoraitisS P Langdon
Jun 1, 2000·Metabolism: Clinical and Experimental·K H PoldermanL J Gooren
Oct 29, 2000·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·A VenutiA Bagnato
Apr 17, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael A CarducciRobert J Padley
Feb 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael A CarducciJoel B Nelson
Sep 24, 2016·Journal of Applied Physiology·Görel NymanGöran Hedenstierna

❮ Previous
Next ❯

Citations

May 15, 2008·Neuro-oncology·Surasak PhuphanichUNKNOWN New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium
Mar 13, 2014·Cancer Chemotherapy and Pharmacology·Islam R YounisWilliam P Petros
Jul 9, 2005·Expert Review of Anticancer Therapy·Antonio Jimeno, Michael Carducci
Nov 30, 2004·Expert Opinion on Investigational Drugs·Antonio Jimeno, Michael Carducci
Dec 7, 2007·Cancer Investigation·Mihailo LalichGlenn Liu
Jul 4, 2012·Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy·Abbul Bashar Khan Kabir-Ud-Din
Jul 6, 2011·Colloids and Surfaces. B, Biointerfaces·Abbul Bashar Khan Kabir-ud Din
Jan 8, 2005·Clinical Prostate Cancer·Robert B HegemanDouglas G McNeel
Mar 29, 2007·Journal of Clinical Pharmacology·Hao XiongDarryl J Sleep
Oct 13, 2005·Pharmacology & Therapeutics·Sophie MotteRobert Naeije
Mar 13, 2015·European Biophysics Journal : EBJ·Sonali M ShiriskarBasir Ahmad
Aug 19, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mrinal M GounderPatrick Y Wen
Mar 22, 2020·Journal of Clinical Medicine·Frederik C EnevoldsenMarcus Krüger
Mar 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alberto A ChiapporiGerold Bepler
Oct 26, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael A Carducci, Antonio Jimeno
Jul 1, 2020·Langmuir : the ACS Journal of Surfaces and Colloids·Atanu NandySaptarshi Mukherjee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.